circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-31. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Dynamic and interactive HTML5 charting Improved and revamped scheduler (additional features over what is added in CF10 Standard) Object relational mapping enhancements The lists above were obtained from the Adobe web site pages describing "new features", as listed first in the links in the following list. CF10 was originally referred to by the codename Zeus, after first being confirmed as coming by Adobe at Adobe MAX 2010, and during much of its prerelease period. It was also commonly referred to as "ColdFusion next" and "ColdFusion X" in blogs, on Twitter, etc., before Adobe finally confirmed it would be "ColdFusion 10". For much of 2010, ColdFusion Product Manager Adam Lehman toured the US setting up countless meetings with customers, developers, and user groups to formulate a master blueprint for the next feature set. In September 2010, he presented the plans to Adobe where they were given full support and approval by upper management. The first public beta of ColdFusion 10 was released via Adobe Labs on 17 February 2012.
=== Education === Platt attended a progressive boarding school named Colorado Rocky Mountain School in Carbondale, Colorado. Platt majored in drama at Tufts University, where he met and became close friends with Hank Azaria. He spent three years working in theatre in Boston, Massachusetts, which he said had a "wealth of serious amateur theatre at that time…I played many roles, and it was the best training I could have had." Platt travelled with Shakespeare and Company, based in Lenox, Massachusetts, touring schools to earn his Equity card, before moving to New York. Platt's early career involved Off-Broadway and regional theatre, and he appeared onstage with the New York Shakespeare Festival, Lincoln Center Theater, Manhattan Theatre Club and other companies across many genres. He obtained an agent while working at Manhattan Punch Line Theatre, and met actor Bill Murray at his cousin's Christmas party. Murray attended Platt's show and recommended Platt to director Jonathan Demme, who cast him in Married to the Mob in 1988. Platt attributes his breakthrough to appearing at the Punch Line Theater.
=== P187s === One widespread single-nucleotide polymorphism of the NQO1 gene (NQO1*2), found homozygous in 4% to 20% of different populations, has found to be connected with different forms of cancer and a lowered efficiency of some chemotherapeutics like mitomycin C. This single nucleotide polymorphism leads to a proline serine exchange on position 187. NAD(P)H dehydrogenase [quinone] 1 P187S has been shown to have a lowered activity and stability. Crystallographic and nuclear magnetic resonance data show that the reason for this different behaviour is found in a flexible C-terminus of the protein leading to a destabilization of the whole protein. Recent pharmacological research suggests feasibility of genotype-directed redox chemotherapeutic intervention targeting NQO1*2 breast cancer. A comprehensive meta-analysis showed an association between overall cancer risk and P187S.
The targeting of hospitals, as well as religious sites, constitutes a war crime. Lebanese health minister Firass Abiad said that 163 rescuers and health workers were killed and 273 others were injured in Lebanon since the start of Israel–Hezbollah conflict. Human Rights Watch stated that Israel's "repeated" attacks on medical workers and healthcare facilities were apparent war crimes. The IDF shelled Meiss Ej Jabal Hospital, injuring a doctor on 10 November 2023. The missiles did not explode but caused damage to the emergency department and several cars. Lebanon's Ministry of Public Health condemned the attack, saying that "Israeli authorities were fully responsible for this unjustifiable act, which would have led to catastrophic results", and called for an investigation. Days before, four people were reportedly injured after an Israeli bombing that hit two ambulances. The Lebanese National News Agency said that an Israeli drone strike hit two ambulances belonging to the Risala Scout Association, which is affiliated with the Amal Movement. On 26 December 2023, an anti-tank missile shot by Hezbollah fighters from Lebanon damaged a shed in a church compound in Iqrit, but not the church itself, wounding an elderly civilian. As IDF troops and medical services were working to evacuate him, they were hit by further missiles, which resulted in nine soldiers being wounded, one of them seriously. On 11 January 2024, the IDF conducted strikes in the town of Hanine and targeted an emergency center affiliated with the Hezbollah-linked Islamic Health Authority.
Sources: en.wikipedia.org
=== Welsh poet === Thomas disliked being regarded as a provincial poet and decried any notion of 'Welshness' in his poetry. When he wrote to Stephen Spender in 1952, thanking him for a review of his Collected Poems, he added "Oh, & I forgot. I'm not influenced by Welsh bardic poetry. I can't read Welsh." Despite this his work was rooted in the geography of Wales. Thomas acknowledged that he returned to Wales when he had difficulty writing, and John Ackerman argues that "His inspiration and imagination were rooted in his Welsh background". Caitlin Thomas wrote that he worked "in a fanatically narrow groove, although there was nothing narrow about the depth and understanding of his feelings. The groove of direct hereditary descent in the land of his birth, which he never in thought, and hardly in body, moved out of." Head of Programmes Wales at the BBC, Aneirin Talfan Davies, who commissioned several of Thomas's early radio talks, believed that the poet's "whole attitude is that of the medieval bards." Kenneth O. Morgan counter-argues that it is a 'difficult enterprise' to find traces of cynghanedd (consonant harmony) or cerdd dafod (tongue-craft) in Thomas's poetry.
In Virus (2019), directed by Aashiq Abu, Kallingal played nurse Akhila, a character based on Lini Puthussery — the nurse who died treating Kerala's first patient in the 2018 Nipah virus outbreak. Lini Puthussery's husband, who attended a screening of the film, said that Kallingal's portrayal was faithful and delivered "a flawless performance as Lini". Kallingal co-produced the film with Aashiq Abu under their production banner OPM Cinemas. Sowmya Rajendran described her performance as "expressive". In the 2021 film Santhoshathinte Onnam Rahasyam, directed by Don Palathara, Kallingal played an entertainment journalist opposite Jitin Puthenchery. Baradwaj Rangan described her performance as "terrific". The film won her Best Actress at the Diorama International Film Festival. In 2023 she appeared in Neelavelicham, a horror drama co-produced with Aashiq Abu. In 2025, Kallingal starred in Theatre, written and directed by Sajin Baabu, playing Meera, a woman who has lived an isolated life on a coastal Kerala island alongside her elderly mother. The film explores the conflict between traditional belief and modern science. The film had its world premiere at the Eurasian Bridge International Film Festival in Yalta on 9 October 2025, before its theatrical release on 16 October 2025. The role was physically demanding; director Sajin Baabu noted that Kallingal spent several hours atop a coconut tree for a single scene and completed multiple retakes despite sustaining bruises.
== Synthesis == The preparation of acifluorfen first described in the Rohm & Haas patent includes as its final steps an Ullmann condensation between 2-chloro-4-trifluoromethylphenol and 2-nitro-5-fluorobenzonitrile. The intermediate is then hydrolysed using hydrobromic acid in acetic acid as solvent.
Sources: en.wikipedia.org
Sean Kinney said about the new album and the fans' mixed reactions about the band moving on after Staley's death: Look, it's a big move to fucking stand up and move on. Some people, the music connected with them so strongly, their opinions, how they feel about it ... It's amazing that they have such a connection but they seem to act like it happened to them. This happened to us and Layne's family, not them. This is actually our lives. If we're okay with it, why can't you be? This happened to us, this didn't happen to you. But this album isn't about that, it's a bigger universal point. We're all going to fucking die, we're all going to lose somebody, and it fucking hurts. How do you move on? This record is us moving on, and hurting. That, to me, is a victory. I already feel like I've won. Sometimes people ask us, 'Wouldn't Layne have been pissed off that we did this?' And I tell them it would have been the opposite: he would have been pissed off that it took us so long to do this. We're not doing this for money; there is no money in the music business anymore. Jerry and I funded the whole album, and we spent lots of our own money, because we believe in this. And one of the reasons I'm doing this is so more light is turned on to something where the light was turned off. And Cantrell added: "We've toured around the world, we've lost some friends, we buried a dear friend, and somebody that you just can't fucking replace, and then we've chosen by circumstance to get together again.
Brettanomyces (Teleomorph Dekkera) Candida (Teleomorphs for different species from several genera including Pichia, Metschnikowia, Issatchenkia, Torulaspora and Kluyveromyces) Kloeckera (Teleomorph Hanseniaspora), usually the most common "wild yeast" found in the vineyard. Some species are known as "killer yeast" that produce inhibitory levels of ethyl acetate and acetic acid that can kill off sensitive strains of Saccharomyces cerevisiae Saccharomycodes Schizosaccharomyces, the only wine yeast that reproduced by fission whereas most wine yeast reproduce by budding. Zygosaccharomyces, very alcohol-tolerant and can grow in wines up to 18% v/v. Additionally this yeast can survive in extremely high sugar levels (as much as 60% w/w or 60 Brix) and is very resistant to sulfur dioxide. Aureobasidium, particularly the "black yeast" species of Aureobasidium pullulans found in moist cellars that can contaminate aging wine in barrels.
Diatomaceous earth ( DY-ə-tə-MAY-shəs), also known as diatomite ( dy-AT-ə-myte), celite, or kieselgur, is a naturally occurring, soft, siliceous sedimentary rock that can be crumbled into a fine white to off-white powder. It has a particle size ranging from more than 3 mm to less than 1 μm, but typically 10 to 200 μm. Depending on the granularity, this powder can have an abrasive feel, like that of pumice powder, and has a low density as a result of its high porosity. The typical chemical composition of oven-dried diatomaceous earth is 80–90% silica, with 2–4% alumina (attributed mostly to clay minerals), and 0.5–2% iron oxide. Diatomaceous earth consists of the fossilized remains of diatoms, a type of hard-shelled microalgae, that have accumulated over millions of years. It is used as a filtration aid, mild abrasive in products including metal polishes and toothpaste, mechanical insecticide, absorbent for liquids, matting agent for coatings, reinforcing filler in plastics and rubber, anti-block in plastic films, porous support for chemical catalysts, cat litter, activator in coagulation studies, stabilizing component of dynamite, thermal insulator, and soil for potted plants and trees as in the art of bonsai. It is also used in gas chromatography packed columns made with glass or metal as stationary phase.
The end of the Hundred Years War in 1453 meant that Britain, and thus Bristol, lost its access to Gascon wines and so imports of Spanish and Portuguese wines increased. Imports from Ireland included fish, hides and cloth (probably linen). Exports to Ireland included broadcloth, foodstuffs, clothing and metals. It has been suggested that the decline of Bristol's Iceland trade for 'stockfish' (freeze dried cod) was a hard blow to the local economy, encouraging Bristol merchants to turn west, launching unsuccessful voyages of exploration in the Atlantic by 1480 in search of the phantom island of Hy-Brazil. More recent research, however, has shown that the Iceland trade was never more than a minor part of Bristol's overseas trade and that the English fisheries off Iceland actually increased during the late 15th and 16th centuries. In 1487, when king Henry VII visited the city, the inhabitants complained about their economic decline. Such complaints, however, were not uncommon among corporations that wished to avoid paying taxes, or which hoped to secure concessions from the Crown. In reality, Bristol's customs accounts show that the port's trade was growing strongly during the last two decades of the fifteenth century. In great part this was due to the increase of trade with Spain.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.